April 2018 Issue Table Of Contents

From The Editor

• Breakthroughs, Patients, Pricing, And Profits

Feature Articles

• Alnylam – Poised To Deliver Its Breakthrough In 2018
• Reata Pharmaceuticals: Return & Reach Beyond

Capitol Perspectives

• Vertical Mergers Of Rx Supply Chain Spark Antitrust Concerns

Patient Perspectives

• Making No Cents: The Hidden Cost Of American Illness

Companies To Watch

• CytoDyn

Industry Research

• 10 Years Of CRO Performance

Industry Leader

• Cell And Gene Therapies: Driving Innovation For Logistical Solutions

Inside The Industry

• 3 Operating Principles For Successful Drug Development
• Does The U.S. Biosimilar Space Have A Case Of “Progressophobia”?
• Is Blockchain The Right Technology For The Pharma Supply Chain?
• Batter Up: The Starting 9 GDPR Takeaways For CROs
• An Rx For Change That Inspires Trust
• Can A P3 Reduce Attrition Of Drug Candidates?
• Inside The Mind Of Life Science Innovator Mir Imran
• What The 2018 Tax Reform Law Means For Life Sciences
• Pharmas That Build Unique Corporate Cultures

Leadership Lessons

• Extreme Teaming In An Uncertain World

Ask The Board

• Any Suggestions For How To Work With Public-Sector Customers?
• Why Are We Seeing Fewer Companies Willing To Make Older Generic Drugs, And What Can Be Done To Fix This Problem?
• What Advice Do You Have For People Starting A Biopharma Company?